CS
BCAB icon

Candriam SCA’s BioAtla BCAB Stock Holding History

Candriam SCA’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,308
Closed -$3.86M – 737
2023
Q1 		$3.86M Sell
31,308
-4,800
-13% -$865K 0.03% 421
2022
Q4 		$14.9M Sell
36,108
-2,100
-5% -$871K 0.1% 203
2022
Q3 		$14.7M Buy
38,208
+30,567
+400% +$10M 0.1% 205
2022
Q2 		$1.09M Hold
7,641
– – 0.01% 612
2022
Q1 		$1.91M Sell
7,641
-452
-6% -$189K 0.01% 551
2021
Q4 		$7.94M Hold
8,093
– – 0.05% 293
2021
Q3 		$11.9M Buy
8,093
+5,501
+212% +$10.7M 0.08% 243
2021
Q2 		$5.49M Buy
+2,592
New +$5.86M 0.04% 387

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Candriam SCA's BCAB Position: Q2 2023 in Review

Candriam SCA sold out of BioAtla (BCAB) in Q2 2023, closing a stake of 31,308 shares — an estimated $3.86M sold.

Candriam SCA first reported a position in BCAB in Q2 2021 and held it in 8 quarters. The position peaked at $14.9M in Q4 2022. 87 funds tracked by Wall St. Rank hold BCAB as of Q2 2023.

  • Candriam SCA reported no remaining BioAtla position as of Q2 2023 after selling out during the quarter.
  • Candriam SCA sold 31,308 BioAtla shares in Q2 2023, an estimated $3.86M.
  • Candriam SCA first reported a position in BioAtla in Q2 2021 and held it in 8 quarters.
  • Candriam SCA's BioAtla position peaked at $14.9M in Q4 2022.
  • 87 funds tracked by Wall St. Rank held BioAtla as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.